Public Sector Pension Investment Board Purchases 28,866 Shares of Glaukos Corporation $GKOS

Public Sector Pension Investment Board grew its position in Glaukos Corporation (NYSE:GKOS) by 14.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 223,708 shares of the medical instruments supplier’s stock after buying an additional 28,866 shares during the quarter. Public Sector Pension Investment Board owned 0.39% of Glaukos worth $18,243,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GKOS. State Street Corp increased its stake in Glaukos by 5.3% in the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock valued at $215,914,000 after acquiring an additional 105,972 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after purchasing an additional 68,497 shares during the last quarter. Primecap Management Co. CA raised its holdings in shares of Glaukos by 50.0% during the 2nd quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after buying an additional 609,523 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Glaukos by 9.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,330,593 shares of the medical instruments supplier’s stock worth $137,454,000 after buying an additional 115,529 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in shares of Glaukos by 7.7% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,167,853 shares of the medical instruments supplier’s stock worth $120,628,000 after buying an additional 83,669 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

GKOS has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their target price on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Piper Sandler reiterated an “overweight” rating and set a $165.00 price objective on shares of Glaukos in a research report on Wednesday, January 14th. BTIG Research increased their price objective on shares of Glaukos from $123.00 to $131.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Stifel Nicolaus boosted their target price on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $132.54.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 19,340 shares of Glaukos stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the transaction, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at approximately $8,312,940. The trade was a 17.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas William Burns sold 186,945 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the sale, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. This trade represents a 54.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 329,655 shares of company stock worth $37,752,234 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Glaukos Trading Up 2.6%

GKOS opened at $109.51 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $161.78. The company’s 50 day moving average price is $114.64 and its two-hundred day moving average price is $98.00. The firm has a market capitalization of $6.29 billion, a price-to-earnings ratio of -71.11 and a beta of 0.70.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.